Search hospitals > Oregon > Gresham

Legacy Mount Hood Medical Center

Claim this profile
Gresham, Oregon 97030
Global Leader in Cancer
Global Leader in Breast Cancer
Conducts research for Lung Cancer
Conducts research for Adenocarcinoma
Conducts research for Tumors
171 reported clinical trials
6 medical researchers
Photo of Legacy Mount Hood Medical Center in GreshamPhoto of Legacy Mount Hood Medical Center in GreshamPhoto of Legacy Mount Hood Medical Center in Gresham

Summary

Legacy Mount Hood Medical Center is a medical facility located in Gresham, Oregon. This center is recognized for care of Cancer, Breast Cancer, Lung Cancer, Adenocarcinoma, Tumors and other specialties. Legacy Mount Hood Medical Center is involved with conducting 171 clinical trials across 307 conditions. There are 6 research doctors associated with this hospital, such as Andrew Y. Kee, Colleen C. McCormick, Mei Dong, and Jacqueline Vuky, MD.

Area of expertise

1Cancer
Global Leader
Legacy Mount Hood Medical Center has run 52 trials for Cancer. Some of their research focus areas include:
Stage IV
Stage III
ER positive
2Breast Cancer
Global Leader
Legacy Mount Hood Medical Center has run 46 trials for Breast Cancer. Some of their research focus areas include:
ER positive
HER2 negative
HER2 positive

Top PIs

Clinical Trials running at Legacy Mount Hood Medical Center

Breast Cancer
Prostate Cancer
Lung Cancer
Gallbladder Cancer
Non-Small Cell Lung Cancer
Prostate Adenocarcinoma
Cancer
Rectal Cancer
Laryngeal Cancer
Meningioma
Image of trial facility.

Radiation and HER2-Targeted Therapy

for Breast Cancer

This Phase III trial compares the recurrence-free interval (RFI) among patients with early-stage, low risk HER2+ breast cancer who undergo breast conserving surgery and receive HER2-directed therapy, and are randomized to not receive adjuvant breast radiotherapy versus those who are randomized to receive adjuvant radiotherapy per the standard of care.
Recruiting2 awards Phase 315 criteria
Image of trial facility.

Shorter Chemo-Immunotherapy Without Anthracyclines

for Breast Cancer

This phase III trial compares the effects of shorter chemotherapy (chemo)-immunotherapy without anthracyclines to usual chemo-immunotherapy for the treatment of early-stage triple negative breast cancer. Paclitaxel is in a class of medications called anti-microtubule agents. It stops cancer cells from growing and dividing and may kill them. Carboplatin is in a class of medications known as platinum-containing compounds. It works in a way similar to the anticancer drug cisplatin, but may be better tolerated than cisplatin. Carboplatin works by killing, stopping or slowing the growth of cancer cells. Cyclophosphamide is in a class of medications called alkylating agents. It works by damaging the cell's deoxyribonucleic acid (DNA) and may kill cancer cells. It may also lower the body's immune response. Docetaxel is in a class of medications called taxanes. It stops cancer cells from growing and dividing and may kill them. Doxorubicin is an anthracycline chemotherapy drug that damages DNA and may kill cancer cells. Pembrolizumab may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Shorter treatment without anthracycline chemotherapy may work the same as the usual anthracycline chemotherapy treatment for early-stage triple negative breast cancer.
Recruiting2 awards Phase 347 criteria
Image of trial facility.

Durvalumab + Chemotherapy

for Breast Cancer

This phase III trial compares the addition of an immunotherapy drug (durvalumab) to usual chemotherapy versus usual chemotherapy alone in treating patients with MammaPrint Ultrahigh (MP2) stage II-III hormone receptor positive, HER2 negative breast cancer. Immunotherapy with monoclonal antibodies, such as durvalumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Chemotherapy drugs, such as paclitaxel, doxorubicin, and cyclophosphamide work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. There is some evidence from previous clinical trials that people who have a MammaPrint Ultrahigh Risk result may be more likely to respond to chemotherapy and immunotherapy. Adding durvalumab to usual chemotherapy may be able to prevent the cancer from returning for patients with MP2 stage II-III hormone receptor positive, HER2 negative breast cancer.
Recruiting2 awards Phase 340 criteria

Similar Hospitals nearby

Frequently asked questions

What kind of research happens at Legacy Mount Hood Medical Center?
Legacy Mount Hood Medical Center is a medical facility located in Gresham, Oregon. This center is recognized for care of Cancer, Breast Cancer, Lung Cancer, Adenocarcinoma, Tumors and other specialties. Legacy Mount Hood Medical Center is involved with conducting 171 clinical trials across 307 conditions. There are 6 research doctors associated with this hospital, such as Andrew Y. Kee, Colleen C. McCormick, Mei Dong, and Jacqueline Vuky, MD.